Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
9(100.0%)
9Total
Phase 1(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06816992Phase 1Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Role: lead

NCT05413421Phase 1Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Role: lead

NCT05315700Phase 1Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Role: lead

NCT05227144Phase 1Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT06012721Phase 1Completed

Effect of Food on the Pharmacokinetics of ORIC-114

Role: lead

NCT04033328Phase 1Terminated

Study of ORIC-101 in Combination With Enzalutamide

Role: lead

NCT03928314Phase 1Terminated

Study of ORIC-101 in Combination With Anticancer Therapy

Role: lead

NCT03835637Phase 1Completed

Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

Role: lead

NCT03324555Phase 1Completed

Study of ORIC-101 in Healthy Adult Subjects

Role: lead

All 9 trials loaded